Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy

The efficacy of amiodarone was assessed in 38 patients with atrial fibrillation resistant to quinidine and an effort made to identify factors correlated with amiodarone response. The study group included 29 patients with and 9 without organic heart disease and either persistent (n = 11) or paroxysmal (n = 27) atrial fibrillation. All patients were treated with amiodarone and followed up in a research clinic. Efficacy was classified as excellent (no recurrent symptomatic atrial fibrillation) in 15 (55%) of 27 patients with paroxysmal and 5 (45%) of 11 patients with persistent atrial fibrillation. Efficacy was poor (no effect on atrial fibrillation) in 5 (19%) of 27 patients with paroxysmal and 6 (55%) of 11 patients with persistent atrial fibrillation. Efficacy was good (amelioration but not total suppression) in 7 (26%) of 27 patients with paroxysmal atrial fibrillation. Efficacy was related to echocardiographic left atrial dimension, left ventricular ejection fraction and, in patients with persistent atrial fibrillation, the duration of the arrhythmia. During the follow-up period of 15 months (range 1 to 36), overall efficacy (considering response and toxicity) was 67% in the 27 patients with paroxysmal and 45% in the 11 patients with persistent atrial fibrillation. It is concluded that amiodarone offers an additional therapeutic alternative in quinidine-resistant atrial fibrillation and that certain clinical factors are correlated with amiodarone response.

This article has been cited by other articles:

				Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF]

				A. Capucci and D. Aschieri Antiarrhythmic drug therapy: what is certain and what is to come Eur. Heart J. Suppl., September 1, 2003; 5(suppl_H): H8 - H18. [Abstract] [PDF]

				R. J Schilling Which patient should be referred to an electrophysiologist: supraventricular tachycardia Heart, March 1, 2002; 87(3): 299 - 304. [Full Text] [PDF]

				Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology Eur. Heart J., October 2, 2001; 22(20): 1852 - 1923. [PDF]

				V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1266 - 1266. [Full Text] [PDF]

				A Capucci, G.Q Villani, D Aschieri, A Rosi, and M.F Piepoli Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation Eur. Heart J., January 1, 2000; 21(1): 66 - 73. [Abstract] [PDF]

				G. Cotter, A. Blatt, E. Kaluski, E. Metzkor-Cotter, M. Koren, I. Litinski, R. Simantov, Y. Moshkovitz, R. Zaidenstein, E. Peleg, et al. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study Eur. Heart J., December 2, 1999; 20(24): 1833 - 1842. [Abstract] [PDF]

				E. Catherwood, W. D. Fitzpatrick, M. L. Greenberg, P. T. Holzberger, D. J. Malenka, B. R. Gerling, and J. D. Birkmeyer Cost-Effectiveness of Cardioversion and Antiarrhythmic Therapy in Nonvalvular Atrial Fibrillation Ann Intern Med, April 20, 1999; 130(8): 625 - 636. [Abstract] [Full Text] [PDF]

				C.J. Meurling, M.P. Ingemansson, A. Roijer, J. Carlson, C.J. Lindholm, B. Smideberg, L. Sorno, M. Stridh, and S.B. Olsson Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil Europace, January 1, 1999; 1(4): 234 - 241. [Abstract] [PDF]

				P. C. Deedwania, B. N. Singh, K. Ellenbogen, S. Fisher, R. Fletcher, and S. N. Singh Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients With Heart Failure and Atrial Fibrillation : Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Circulation, December 8, 1998; 98(23): 2574 - 2579. [Abstract] [Full Text] [PDF]

				W.-C. Yu, S.-A. Chen, S.-H. Lee, C.-T. Tai, A.-N. Feng, B. I.-T. Kuo, Y.-A. Ding, and M.-S. Chang Tachycardia-Induced Change of Atrial Refractory Period in Humans : Rate Dependency and Effects of Antiarrhythmic Drugs Circulation, June 16, 1998; 97(23): 2331 - 2337. [Abstract] [Full Text] [PDF]

				Y.-G. Li and S. H. Hohnloser Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control? Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 185 - 194. [Abstract] [PDF]

				B. N. Singh and B. Lopez Atrial Fibrillation: Defining Some Unanswered Questions Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 195 - 199. [PDF]

				E. G. Daoud, S. A. Strickberger, K. C. Man, R. Goyal, G. M. Deeb, S. F. Bolling, F. D. Pagani, C. Bitar, M. D. Meissner, and F. Morady Preoperative Amiodarone as Prophylaxis against Atrial Fibrillation after Heart Surgery N. Engl. J. Med., December 18, 1997; 337(25): 1785 - 1791. [Abstract] [Full Text] [PDF]

				M. Brignole, L. Gianfranchi, C. Menozzi, P. Alboni, G. Musso, M. G. Bongiorni, M. Gasparini, A. Raviele, G. Lolli, N. Paparella, et al. Assessment of Atrioventricular Junction Ablation and DDDR Mode-Switching Pacemaker Versus Pharmacological Treatment in Patients With Severely Symptomatic Paroxysmal Atrial Fibrillation : A Randomized Controlled Study Circulation, October 21, 1997; 96(8): 2617 - 2624. [Abstract] [Full Text]

				M. A. Brodsky, J. G. Chun, P. J. Podrid, S. Douban, B. J. Allen, and R. Cygan Regional Attitudes of Generalists, Specialists, and Subspecialists About Management of Atrial Fibrillation Arch Intern Med, December 9, 1996; 156(22): 2553 - 2562. [Abstract] [PDF]

				I. C. Van Gelder, H. J. G. M. Crijns, R. G. Tieleman, J. Brugemann, P. J. De Kam, A. T. M. Gosselink, F. W. A. Verheugt, and K. I. Lie Chronic Atrial Fibrillation: Success of Serial Cardioversion Therapy and Safety of Oral Anticoagulation Arch Intern Med, December 9, 1996; 156(22): 2585 - 2592. [Abstract] [PDF]

				J. Altamirano, D. M. Gallik, and B. N. Singh Controlling Paroxysmal Atrial Fibrillation by a Combination of Amiodarone and Flecainide: Description of a Case With 15-Year Follow-up Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 1996; 1(4): 333 - 338. [Abstract] [PDF]

				E. N. Prystowsky, D. W. Benson Jr, V. Fuster, R. G. Hart, G. N. Kay, R. J. Myerburg, G. V. Naccarelli, and D. G. Wyse Management of Patients With Atrial Fibrillation : A Statement for Healthcare Professionals From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association Circulation, March 15, 1996; 93(6): 1262 - 1277. [Full Text]

				A. P. Aboaf and P. S. Wolf Paroxysmal Atrial Fibrillation: A Common but Neglected Entity Arch Intern Med, February 26, 1996; 156(4): 362 - 367. [Abstract] [PDF]

				D. G. Zarembski, P. E. Nolan Jr, M. K. Slack, and A. C. Caruso Treatment of Resistant Atrial Fibrillation: A Meta-analysis Comparing Amiodarone and Flecainide Arch Intern Med, September 25, 1995; 155(17): 1885 - 1891. [Abstract] [PDF]

				H. R. Middlekauff, W. G. Stevenson, and J. A. Gornbein Antiarrhythmic Prophylaxis vs Warfarin Anticoagulation to Prevent Thromboembolic Events Among Patients With Atrial Fibrillation: A Decision Analysis Arch Intern Med, May 8, 1995; 155(9): 913 - 920. [Abstract] [PDF]

				A. T. M. Gosselink, H. J. G. M. Crijns, I. C. Van Gelder, H. Hillige, A. C. P. Wiesfeld, and K. I. Lie Low-Dose Amiodarone for Maintenance of Sinus Rhythm After Cardioversion of Atrial Fibrillation or Flutter JAMA, June 24, 1992; 267(24): 3289 - 3293. [Abstract] [PDF]

				H. R. Middlekauff, I. Wiener, L. A. Saxon, and W. G. Stevenson Low-Dose Amiodarone for Atrial Fibrillation: Time for a Prospective Study? Ann Intern Med, June 15, 1992; 116(12_Part_1): 1017 - 1020. [Abstract] [PDF]